10-Q: Inhibikase Therapeutics Reports First Quarter 2024 Financial Results and Provides Clinical Program Update

Inhibikase Therapeutics reported its first quarter 2024 financial results, highlighting progress in its clinical programs for Parkinson's disease and other neurodegenerative disorders.

Summary

• Inhibikase Therapeutics reported a net loss of $4.65 million for the three months ended March 31, 2024, compared to a net loss of $4.48 million for the same period in 2023.
• The company's research and development expenses decreased slightly to $2.75 million from $2.85 million year-over-year.
• Selling, general, and administrative expenses increased to $2.03 million from $1.93 million in the prior year.
• The company's cash and cash equivalents stood at $2.35 million, with marketable securities at $7.40 million as of March 31, 2024.
• The company has working capital of $6.57 million and an accumulated deficit of $71.55 million.
• The company estimates its working capital is sufficient to fund operations through November 2024.
• The company sold 290,564 shares through an At-The-Market offering, generating net proceeds of $397,607.
• The company's Phase 2 program for Risvodetinib in Parkinson's disease has enrolled 99 participants across 32 active sites, with 44 participants completing the 12-week dosing period.
• The company is planning to extend the Phase 2 trial by up to 12 months, subject to additional resources.
• The company is also planning a Phase 2 study in Multiple System Atrophy (MSA) patients in the EU and US.
• The company is advancing IkT-001Pro, a prodrug for imatinib, and has completed a pre-NDA meeting with the FDA.
• The company is also exploring IkT-001Pro for pulmonary arterial hypertension (PAH) and has had a pre-IND meeting with the FDA.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and potential new indications, the company's financial situation is precarious, with a limited cash runway and increasing losses. The legal challenge adds further uncertainty. The sentiment is therefore cautiously negative.

Positives

• The company has made progress in its Phase 2 clinical trial for Parkinson's disease, with 99 participants enrolled and 44 completing the initial dosing period.
• The company is planning to extend the Phase 2 Parkinson's trial by up to 12 months, which could provide more comprehensive data.
• The company has received Orphan Drug Designation for Risvodetinib for the treatment of MSA.
• The company has completed a pre-NDA meeting with the FDA for IkT-001Pro, which is a step towards potential approval.
• The company is exploring IkT-001Pro for PAH, which could expand its market opportunities.
• The company has a strong patent portfolio with protection until 2033 for IkT-001Pro and 2036 for Risvodetinib.
• The company has improved drug delivery of Risvodetinib through a tablet formulation, which nearly doubled the concentration delivered.

Negatives

• The company reported a net loss of $4.65 million for the quarter, indicating ongoing financial challenges.
• The company's working capital is only estimated to be sufficient to fund operations through November 2024, raising concerns about its ability to continue as a going concern.
• The company has an accumulated deficit of $71.55 million, highlighting its history of losses.
• The company's grant revenue decreased by 100% compared to the same period last year.
• The company is facing a legal challenge from Pivot Holding LLC, seeking $1.625 million in milestone payments plus interest.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and limited working capital.
• The company may not be able to raise additional capital on commercially favorable terms, which could impact its ability to fund clinical trials and operations.
• The company is subject to risks associated with drug development, including regulatory approvals, clinical trial outcomes, and market acceptance.
• The company is facing a legal claim for $1.625 million plus interest, which could impact its financial resources.
• The company's reliance on third-party suppliers and research institutions poses risks to its operations.
• The company's success is highly dependent on the success of its initial product candidates targeting neurodegenerative diseases.
• The company may encounter delays in its current and planned clinical trials.
• The company may not be able to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates.

Future Outlook

The company anticipates costs and expenses to increase as it continues to develop its product candidates. The company may seek to fund its operations through additional public equity, private equity, or debt financings, as well as other sources. The company estimates that its working capital at March 31, 2024, including the funds raised from the February 2024 At the Market Offering, is sufficient to fund its normal operations through November 2024. The company plans to extend the Phase 2 Parkinson's trial by up to 12 months, subject to additional resources. The company also plans to initiate a Phase 2 study in MSA patients in the EU and US and submit regulatory documents to European Union authorities in 2024. The company is also evaluating the application of IkT-001Pro to pulmonary arterial hypertension (PAH).

Management Comments

• Management believes that the company's approach to Parkinson's disease and other neurological diseases has identified the underlying cause of disease.
• Management believes that the company's approach to neurodegenerative disease is validated by its 2022 and 2023 publications and oral presentations at major academic and industry conferences.
• Management plans to advance only those candidates to the later stages of clinical development that show strong preclinical and early clinical data.
• Management believes a more rapid path to enrollment is emerging through the public outreach/awareness campaign led by the the201trial.com website.
• Management plans to introduce the tablet formulation of Risvodetinib into the 12-month extension study, once implemented, as well as in all future clinical trials.

Industry Context

The company is operating in the competitive pharmaceutical industry, specifically targeting neurodegenerative diseases, which have seen limited success in drug development. The company's approach to identifying the underlying causes of disease and developing targeted therapies differentiates it from some competitors. The company is also exploring opportunities in orphan indications such as MSA and PAH, which may offer less competition and faster regulatory pathways. The company's focus on improving drug delivery through prodrug technologies and tablet formulations aligns with industry trends towards more effective and patient-friendly treatments.

Comparison to Industry Standards

• The company's cash burn rate is typical for a clinical-stage biotech company, but its cash runway is shorter than some peers, requiring additional capital raises.
• The company's focus on neurodegenerative diseases is in line with a major area of unmet medical need, but the high failure rate in this field presents a significant risk.
• The company's Phase 2 trial for Parkinson's disease is comparable to other trials in the field, but the small sample size of the initial data makes it difficult to draw definitive conclusions.
• The company's development of a prodrug for imatinib is similar to other efforts to improve drug delivery and reduce side effects, but the regulatory pathway for this approach is still uncertain.
• The company's exploration of IkT-001Pro for PAH is a novel approach, but the market for PAH is competitive and the clinical development pathway is complex.
• The company's patent portfolio is a key asset, but the strength and enforceability of these patents will be critical to its long-term success.
• Compared to companies like Biogen, which has faced challenges in Alzheimer's drug development, Inhibikase is taking a different approach by focusing on the underlying biochemistry of the disease process.

Legal Proceedings

• The company received a notice of a demand for arbitration from Pivot Holding LLC, alleging breach of contract and seeking $1.625 million in milestone payments plus interest.

Related Party Transactions

• During the period ended March 31, 2024 and 2023 the Company incurred expenses of approximately $ 90 thousand and $ 0 thousand, respectively with a related party vendor included in research and development expenses.
• As at the period ended March 31, 2024 and December 31, 2023 the Company had a payable balance with a related party vendor of approximately $ 109 thousand and $ 57 thousand, respectively included in accounts payable and accrued expenses.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future equity offerings.
• Employees may be impacted by potential cost-cutting measures or delays in research projects.
• Customers (potential patients) may benefit from the development of new therapies, but the timeline for approval and commercialization is uncertain.
• Suppliers and creditors may be impacted by the company's financial challenges and potential need to reduce expenses.
• The company's ability to continue as a going concern is a significant risk for all stakeholders.

Next Steps

• The company plans to extend the Phase 2 Parkinson's trial by up to 12 months.
• The company plans to initiate a Phase 2 study in MSA patients in the EU and US.
• The company plans to submit regulatory documents for Risvodetinib to European Union authorities in 2024.
• The company plans to complete a comparative cell-culture based study of the hERG ion channel for IkT-001Pro.
• The company plans to file an IND for IkT-001Pro for PAH.
• The company will continue to evaluate research phase molecules for various neurodegenerative disease indications.
• The company will continue to work with the FDA on the approval pathway for IkT-001Pro.
• The company will respond to the demand for arbitration from Pivot Holding LLC by June 17, 2024.

Key Dates

Keywords

Parkinson's disease, Risvodetinib, IkT-148009, Multiple System Atrophy, MSA, IkT-001Pro, imatinib, pulmonary arterial hypertension, PAH, clinical trials, neurodegenerative diseases, biotechnology, pharmaceuticals, Orphan Drug Designation, FDA, pre-NDA, pre-IND, At-The-Market Offering, financial results